ArticleScientific reports2025
Nano-Luciferase complementation assay of human herpesvirus 8 chemo/cytokine-receptor interactions.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Human and viral chemokines differentially modulate G protein signaling, β-arrestin recruitment and chemotaxis mediated by the viral G protein-coupled receptor ORF74.Cell communication and signaling : CCS · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Some viruses encode proteins that mimic host chemokines and/or cytokines to modulate the host immune responses against infection. Human herpesvirus 8 (HHV-8), also termed Kaposi sarcoma-associated herpesvirus (KSHV), encodes three viral CC-type chemokines (vCCLs 1-3) and an interleukin-6 ortholog (vIL-6). Therapeutic targeting of the vCCLs and vIL-6 has yet to be established despite their importance in immune evasion and transformation by HHV-8. The present study aimed to design a robust and straightforward method to assay receptor binding and downstream signaling using a Nano-Luciferase Binary Technology reporter system (NanoBiT); with this approach, we verified the direct interactions of vCCLs 1-3 with their established receptors. Furthermore, screening with a comprehensive set of human chemokine receptors revealed additional vCCL-interacting receptors, including ACKR4. The vCCL-receptor interactions were validated using competition, antibody-mediated neutralization, or mutagenesis of vCCLs. We extended the utility of NanoBiT to assess the intracellular protein-protein interactions involved in vCCL-induced downstream signaling via b-arrestin. Likewise, we used NanoBiT to monitor vIL-6 binding to its receptor gp130 and downstream signaling via STAT3. In sum, we demonstrate the utility of NanoBiT for assessing viral chemo/cytokine-receptor interactions and signaling and its potential in screening for antibodies to treat HHV-8 infection and related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.